The study included 123 patients diagnosed with MDS per the WHO 2008/2016 classification; 98 of them were treated with AZA…The median mRNA levels of RRM1 were 4.2 times higher in non-responders (p=0.019) in comparison to responders….MDS patients with low RRM1 levels had a better response to AZA-treatment.